Retina

The research team is led by Professor Anders Kvanta and Dr Helder André, with a research portfolio to provide unpreceded cellular and molecular mechanistic views on neovascular and degenerative retinal diseases, with high focus on translational sustainable therapy strategies for patients with blinding diseases.

The Kvanta/André group conducts translational studies focused on identifying and improving treatments of several retinal diseases, including retinal degenerations, retinal vein occlusion and diabetic retinopathy. The key area of our current research is age-related macular degeneration (AMD), one of the most common and rapidly increasing sight-threatening diseases. Advanced AMD is a major cause of severe central vision loss affecting more than 180 million people globally (over 100,000 in Sweden). Despite a seemingly low incidence, AMD has one the of fastest rates of increased prevalence in the developed world as a consequence of an aging population, and is estimated to become an immense burden for healthcare systems worldwide, with massive economic implications. Due to the protracted nature of AMD, the multifactorial mechanisms involved, and current therapeutic limitations there is a great need for long-term therapies that can regenerate lost retinal cells or mitigate multiple angiogenic and inflammatory factors known to be associated with AMD, simultaneously allowing for sustainable treatments.

AMD
By elaborating the mechanisms behind retinal diseases and their implications to both physiology and pathology, we can then translate them into future therapies to fight blindness.

Research Projects

The common goal of the Kvanta/André Lab is to develop new treatments for neovascular and degenerative retinal disease. Our experimental projects include molecular and cell biology studies, and preclinical animal models aimed to identify new molecules and pathways relevant to the onset of neovascularization and cell death for these retinal conditions. In addition, preclinical studies are ongoing with gene therapy to treat vascular retinal diseases. Our previous and ongoing research has contributed to the successful development of break-through treatments for wet (neovascular) AMD and has laid the ground for regenerative treatment of dry (degenerative) AMD using human embryonic stem cell (hESC)-derived retinal pigment epithelial cells (RPE).

  • Mechanistic and therapeutic studies on ocular vascular diseases
  • Sustainable gene therapy for neovascular AMD
  • Bench-to-bedside cellular regenerative treatments of dry AMD
  • A platform for cellular regenerative treatments of retinal diseases
  • A preclinical bioengineering approach for the treatment of Diabetes

Read more about the projects

Selected Publications

Echinomycin mitigates ocular angiogenesis by transcriptional inhibition of the hypoxia-inducible factor-1

Flavia Plastino, Álvaro Santana-Garrido, Noemi Anna Pesce, Monica Aronsson, Emma Lardner, Alfonso Mate, Anders Kvanta, Carmen Maria Vázquez, Helder André

Exp Eye Res. 2021 Feb 25;206:108518.doi: 10.1016/j.exer.2021.108518. Online ahead of print.

Identification of cell surface markers and establishment of monolayer differentiation to retinal pigment epithelial cells

Alvaro Plaza Reyes, Sandra Petrus-Reurer, Sara Padrell Sánchez, Pankaj Kumar, Iyadh Douagi, Hammurabi Bartuma, Monica Aronsson, Sofie Westman, Emma Lardner, Helder André, Anna Falk, Emeline F Nandrot, Anders Kvanta, Fredrik Lanner

Nat Commun. 2020 Mar 30;11(1):1609.doi: 10.1038/s41467-020-15326-5.

Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II

Sandra Petrus-Reurer, Nerges Winblad, Pankaj Kumar, Laia Gorchs, Michael Chrobok, Arnika Kathleen Wagner, Hammurabi Bartuma, Emma Lardner, Monica Aronsson, Álvaro Plaza Reyes, Helder André, Evren Alici, Helen Kaipe, Anders Kvanta, Fredrik Lanner

Stem Cell Reports. 2020 Apr 14;14(4):648-662.doi: 10.1016/j.stemcr.2020.02.006. Epub 2020 Mar 19.

Gaining insight on mitigation of rubeosis iridis by UPARANT in a mouse model associated with proliferative retinopathy

Filippo Locri, Noemi A Pesce, Monica Aronsson, Maurizio Cammalleri, Mario De Rosa, Vincenzo Pavone, Paola Bagnoli, Anders Kvanta, Massimo Dal Monte, Helder André

J Mol Med (Berl). 2020 Nov;98(11):1629-1638.doi: 10.1007/s00109-020-01979-8. Epub 2020 Sep 17.

Identification of Diagnostic and Prognostic microRNAs for Recurrent Vitreous Hemorrhage in Patients with Proliferative Diabetic Retinopathy

Parviz Mammadzada, Juliette Bayle, Johann Gudmundsson, Anders Kvanta, Helder André

J Clin Med. 2019 Dec 15;8(12):2217.doi: 10.3390/jcm8122217.

Gene Transfer of Prolyl Hydroxylase Domain 2 Inhibits Hypoxia-inducible Angiogenesis in a Model of Choroidal Neovascularization

Anna Takei, Malena Ekström, Parviz Mammadzada, Monica Aronsson, Ma Yu, Anders Kvanta, Helder André

Sci Rep. 2017 Feb 10;7:42546.doi: 10.1038/srep42546.

OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF THE FOVEAL MICROVASCULATURE IN GEOGRAPHIC ATROPHY

Anders Kvanta, Manuel Casselholm de Salles, Urban Amrén, Hammurabi Bartuma

Observational Study Retina. 2017 May;37(5):936-942.doi: 10.1097/IAE.0000000000001248.

Xeno-Free and Defined Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Functionally Integrate in a Large-Eyed Preclinical Model

Alvaro Plaza Reyes, Sandra Petrus-Reurer, Liselotte Antonsson, Sonya Stenfelt, Hammurabi Bartuma, Sarita Panula, Theresa Mader, Iyadh Douagi, Helder André, Outi Hovatta, Fredrik Lanner, Anders Kvanta

Stem Cell Reports. 2016 Jan 12;6(1):9-17.doi: 10.1016/j.stemcr.2015.11.008. Epub 2015 Dec 24.

Hypoxia-Inducible Factor-1α Is Associated With Sprouting Angiogenesis in the Murine Laser-Induced Choroidal Neovascularization Model

Helder André, Selcuk Tunik, Monica Aronsson, Anders Kvanta

Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6591-604.doi: 10.1167/iovs.15-16476.

Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study

David L J Epstein, Peep V Algvere, Gunvor von Wendt, Stefan Seregard, Anders Kvanta

Ophthalmology. 2012 Jun;119(6):1184-9.doi: 10.1016/j.ophtha.2012.01.022. Epub 2012 Mar 17.

Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study

Anne-Catherine Söderberg, Peep V Algvere, Jürg C Hengstler, Pär Söderberg, Stefan Seregard, Anders Kvanta

Br J Ophthalmol. 2012 May;96(5):714-8.doi: 10.1136/bjophthalmol-2011-300721. Epub 2012 Jan 12.

Biomechanical regulation of blood vessel growth during tissue vascularization

Witold W Kilarski  1 , Branka Samolov, Ludvig Petersson, Anders Kvanta, Pär Gerwins

Nat Med. 2009 Jun;15(6):657-64.doi: 10.1038/nm.1985.

Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor

A Kvanta, P V Algvere, L Berglin, S Seregard

Invest Ophthalmol Vis Sci. 1996 Aug;37(9):1929-34.

Group leaders

 

Anders Kvanta

Professor, Research group leader
K8 Department of Clinical Neuroscience

Helder Andre

Research group leader
K8 Department of Clinical Neuroscience

Group members

Hammurabi Bartuma MD, Senior researcher

Filippo Locri Postdoc

David Brenière-Letuffe Postdoc

Yesenia Ortega-Melin MD, PhD candidate

Flavia Plastino PhD candidate

Jonathan Bernd Research Resident, PhD candidate

David Epstein MD, Senior researcher

Manuel Casselholm De Salles MD, PhD candidate

Laura Armonaite MD, PhD candidate

Group Alumni

Selçuk Tunik, Associate Professor at University of Dicle, Turkey

Effat Alizadeh, Associate Professor at Tabriz University of Medical Sciences, Iran

Jóhann Gu∂mundsson, Head of Ophthalmology at Lanspitali, Iceland

Sandra Petrus-Reurer, Postdoc at Cambridge University, UK

Parviz Mammadzada, MD Ophthalmology Specialist at Örebro hospital, Sweden

Standing funding

·Novo Nordisk Collaborative support

·The ARMEC Lindberg Foundation

·ALF Medicine

·The Swedish Eye Foundation

·The Crown Princess Margareta Association for the Visually Impaired

·The Edwin Jordan Foundation

·KI Foundations and Funds

Interested in joining the Kvanta/André Lab?

Applications for PhD candidate and postdoc positions are very welcomed from applicants with financing. We also encourage early contacts to plan applications for external personal grants.